Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Alnylam Pharmaceuticals, Inc. (ALNY)

212.72   4.23 (2.03%) 11-25 13:00
Open: 207.89 Pre. Close: 208.49
High: 214.26 Low: 206.45
Volume: 356,457 Market Cap: 26,171(M)

Technical analysis

as of: 2022-11-25 1:55:03 PM
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 259.98     One year: 303.66
Support: Support1: 202.71    Support2: 190.42
Resistance: Resistance1: 222.58    Resistance2: 259.98
Pivot: 209.88
Moving Average: MA(5): 210.92     MA(20): 210.16
MA(100): 196.56     MA(250): 169.51
MACD: MACD(12,26): 2.4     Signal(9): 2.7
Stochastic oscillator: %K(14,3): 51.1     %D(3): 50.6
RSI: RSI(14): 54.4
52-week: High: 236.8  Low: 117.58
Average Vol(K): 3-Month: 968 (K)  10-Days: 556 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ ALNY ] has closed below upper band by 35.5%. Bollinger Bands are 50.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 214.5 - 215.56 215.56 - 216.41
Low: 204.56 - 205.98 205.98 - 207.14
Close: 206.5 - 208.65 208.65 - 210.39

Company Description

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Headline News

Tue, 22 Nov 2022
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat

Sat, 05 Nov 2022
Alnylam Pharmaceuticals (ALNY) Investor Presentation - Slideshow (NASDAQ:ALNY) - Seeking Alpha

Mon, 31 Oct 2022
Top 10 Stock Picks of Eli Casdin’s Casdin Capital - Yahoo Finance

Mon, 31 Oct 2022
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Short Interest Up 5.7% in October - MarketBeat

Mon, 31 Oct 2022
Alnylam: Good Start For Amvuttra, Unanswered Regulatory Questions On Onpattro (ALNY) - Seeking Alpha

Fri, 28 Oct 2022
ALNY Reiterates Guidance, TVTX Loss Widens, DXCM Paints Rosy Outlook - Nasdaq

Financial Analysis

Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 123 (M)
Shares Float 122 (M)
% Held by Insiders 0.5 (%)
% Held by Institutions 97.2 (%)
Shares Short 6,030 (K)
Shares Short P.Month 4,540 (K)

Stock Financials

EPS -7.49
EPS Est Next Qtl -1.37
EPS Est This Year -5.2
EPS Est Next Year -5.33
Book Value (p.s.) -0.56
Profit Margin (%) -123.1
Operating Margin (%) -82.4
Return on Assets (ttm) -14.2
Return on Equity (ttm) -343.6
Qtrly Rev. Growth 40.9
Gross Profit (p.s.) 5.72
Sales Per Share 7.81
EBITDA (p.s.) -6.1
Qtrly Earnings Growth 0
Operating Cash Flow -559 (M)
Levered Free Cash Flow -271 (M)

Stock Valuations

PE Ratio -28.41
PEG Ratio 0.1
Price to Book value -386.77
Price to Sales 27.23
Price to Cash Flow -46.79

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.